Clinical trial · Observational
Secondary Central Nervous System Lymphoma Registry - Charité
Non-interventional, Prospective Observational Study of the Treatment Practice of CNS Involvement of Malignant Lymphoma in Routine Clinical Practice
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or outside of trials. In particular, the following questions will be specified: * What therapeutic approaches are being pursued? * What is the clinical outcome of the various treatment options? * What is the frequency of serious adverse events with each therapeutic approach?
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Central Nervous System Lymphoma | Central Nervous System Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Systemic (= localized outside the CNS) lymphoma with secondary CNS involvement at initial diagnosis
- label
- Cohort 2
- description
- CNS relapse of previously systemic lymphoma
Primary outcomes (3)
- measure
- Description of different therapeutic regimens
- timeFrame
- Through study completion, an average of 3 years
- description
- Description of different therapeutic regimens
- measure
- Outcome of different therapeutic regimens
- timeFrame
- Through study completion, an average of 3 years
- description
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: • All patients with SCNSL can and should be included in the registry regardless of which treatment options are used and whether the treatment being given is first-line, recurrence, or maintenance therapy for SCNSL. Exclusion Criteria: • None
References
Publications (1)
- DERIVEDHabringer S, Demel UM, Fietz AK, Lammer F, Schroers R, Hofer S, Bairey O, Braess J, Meier-Stiegen AS, Stuhlmann R, Schmidt-Hieber M, Hoffmann J, Zinngrebe B, Kaiser U, Reimer P, Mohle R, Fix P, Hoffkes HG, Langenkamp U, Buschenfelde CMZ, Hopfer O, Stoltefuss A, La Rosee P, Blasberg H, Jordan K, Kaun S, Meurer A, Unteroberdorster M, von Brunneck AC, Capper D, Heppner FL, Chapuy B, Janz M, Schwartz S, Konietschke F, Vajkoczy P, Korfel A, Keller U. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Eur J Cancer. 2024 Jan;196:113436. doi: 10.1016/j.ejca.2023.113436. Epub 2023 Nov 14. PMID 38008033